Oncternal Therapeutics (NASDAQ:ONCT) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note released on Sunday. The firm issued a hold rating on the stock.

Oncternal Therapeutics Stock Performance

Shares of ONCT stock opened at $0.53 on Friday. The firm has a market cap of $1.56 million, a P/E ratio of -0.05 and a beta of 1.18. The business’s 50 day moving average price is $0.53 and its 200-day moving average price is $0.73. Oncternal Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $9.88.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.